NLS Pharmaceutics Receives Nasdaq Delisting Determination
Ticker: NCEL · Form: 6-K · Filed: May 24, 2024 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | May 24, 2024 |
| Risk Level | high |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, sec-filing, nasdaq
Related Tickers: NLS
TL;DR
Nasdaq is kicking NLS Pharmaceutics off the exchange, big trouble ahead.
AI Summary
NLS Pharmaceutics Ltd. announced on May 22, 2024, that it received an additional staff delisting determination from the Nasdaq Stock Market. This filing is a report of a foreign private issuer and is incorporated by reference into NLS Pharmaceutics' existing F-3 registration statements.
Why It Matters
This development indicates potential delisting from Nasdaq, which could significantly impact the company's stock liquidity and investor confidence.
Risk Assessment
Risk Level: high — Receiving a delisting determination from a major stock exchange like Nasdaq poses a significant risk to the company's continued trading and investor confidence.
Key Players & Entities
- NLS Pharmaceutics Ltd. (company) — The company filing the report and receiving the delisting determination.
- Nasdaq (company) — The stock exchange that issued the delisting determination.
- May 22, 2024 (date) — The date NLS Pharmaceutics announced the receipt of the delisting determination.
FAQ
What is the specific reason for the additional staff delisting determination from Nasdaq?
The filing does not specify the exact reason for the additional staff delisting determination, only that one was received.
What is the date of the press release announcing this determination?
The press release announcing the receipt of the additional staff delisting determination was issued on May 22, 2024.
What is the company's principal executive office address?
The company's principal executive offices are located at The Circle 6, 8058 Zurich, Switzerland.
Which SEC registration statements does this filing incorporate by reference?
This filing is incorporated by reference into NLS Pharmaceutics' Registration Statements on Form F-3 with file numbers 333-262489, 333-268690, and 333-269220.
What is the company's Central Index Key (CIK)?
The company's Central Index Key (CIK) is 0001783036.
Filing Stats: 260 words · 1 min read · ~1 pages · Grade level 10.8 · Accepted 2024-05-24 17:25:03
Filing Documents
- ea0206805-6k_nlsphar.htm (6-K) — 11KB
- ea020680501ex99-1_nlsphar.htm (EX-99.1) — 8KB
- 0001213900-24-046734.txt ( ) — 20KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NLS Pharmaceutics Ltd. Date: May 24, 2024 By: /s/ Alexander Zwyer Name: Alexander Zwyer Title: Chief Executive Officer 2